Who are IgPro20 (low dose)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IgPro20 (high dose), IgM rich Immunoglobin, Immune Globulin (Human), IgPro20, HyQvia, Cuvitru 20 % Injectable Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/igpro20-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

IgPro20 (low dose) — Competitive Intelligence Brief

IgPro20 (low dose) (IgPro20 (low dose)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin replacement therapy. Area: Immunology.

phase 3 Immunoglobulin replacement therapy Polyclonal human IgG Immunology Biologic Live · refreshed every 30 min

Target snapshot

IgPro20 (low dose) (IgPro20 (low dose)) — CSL Behring. IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IgPro20 (low dose) TARGET	IgPro20 (low dose)	CSL Behring	phase 3	Immunoglobulin replacement therapy	Polyclonal human IgG
IgPro20 (high dose)	IgPro20 (high dose)	CSL Behring	phase 3	Immunoglobulin replacement therapy	Polyclonal human IgG
IgM rich Immunoglobin	IgM rich Immunoglobin	Sir Takhtasinhji General Hospital	marketed	Immunoglobulin replacement therapy	IgM antibodies; complement system (C1q)
Immune Globulin (Human)	Immune Globulin (Human)	Grifols Therapeutics LLC	marketed	Immunoglobulin replacement therapy	Multiple pathogenic antigens and pathogens (non-specific)
IgPro20	IgPro20	CSL Behring	marketed	Immunoglobulin replacement therapy	Polyclonal IgG (multiple epitopes)
HyQvia	HyQvia	Takeda	marketed	Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin	Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement
Cuvitru 20 % Injectable Solution	Cuvitru 20 % Injectable Solution	University of Edinburgh	marketed	Immunoglobulin replacement therapy	Fc receptors and complement system (via IgG antibodies)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin replacement therapy class)

CSL Behring · 3 drugs in this class
Grifols Therapeutics LLC · 2 drugs in this class
Baxalta now part of Shire · 1 drug in this class
Biopharma Plasma LLC · 1 drug in this class
Sir Takhtasinhji General Hospital · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IgPro20 (low dose) — Competitive Intelligence Brief. https://druglandscape.com/ci/igpro20-low-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab